|
Biota Holdings targeting asthma market with flu drug
Australian Life Scientist Biota Holdingstoday commenced a 400-member trial in the US of its anti-viral drug BTA798 on sufferers of asthma who have contracted cold and flu. … HRV Phase II Trial Underway in Patients |
View full post on asthma – Google News